Pharmaceutical company Wanbury (NSE:WANBURY, BOM:524212) has begun commercial production for a high-potency anesthetic active pharmaceutical ingredients (API) at the company's Tanku facility in Andhra Pradesh, India, according to a Wednesday filing to the Indian bourses.
The API is expected to generate incremental revenue of around 180 million Indian rupees in the fiscal fourth quarter of the financial year 2025-26.
The company has launched four new anesthetic APIs at its Tanuku manufacturing facility, and targets about 1 billion rupees incremental revenue from this and four new high-value APIs by the financial year 2026-27.
The company's shares were up over 8% in recent trade.
Comments